Haitang Yang
Overview
Explore the profile of Haitang Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
1067
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang H, Pu S, Shu P, Wang J, Chen Y, Yang X, et al.
Bioelectrochemistry
. 2024 Dec;
163:108891.
PMID: 39736194
Early diagnosis of tumors is becoming increasingly important in modern healthcare. As studies have demonstrated, Poly(ADP)ribose polymerase-1 (PARP-1) is overexpressed in more aggressive tumors. Consequently, sensitive detection of PARP-1 activity...
2.
Zhang E, Zhao B, Liu Y, Liu G, Lu S, Xiong L, et al.
STAR Protoc
. 2024 Dec;
5(4):103487.
PMID: 39666459
Lung-draining lymph nodes (LNs) play crucial roles in infection, inflammation, and cancer, but in situ and in vivo studying models are technically challenging. Here, we present a protocol for the...
3.
Zhao L, Deng H, Zhang J, Zamboni N, Yang H, Gao Y, et al.
Cell Death Differ
. 2024 Dec;
PMID: 39643712
Ferroptosis is an oxidative, non-apoptotic cell death frequently inactivated in cancer, but the underlying mechanisms in oncogene-specific tumors remain poorly understood. Here, we discover that lactate dehydrogenase (LDH) B, but...
4.
Yang H, Gu X, Wang Z, Liu G, Niu Y, Pan X, et al.
J Thorac Dis
. 2024 Oct;
16(9):6272-6285.
PMID: 39444874
Background: Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and remains a leading cause of cancer-related death. Lymph node metastasis (LNM) significantly affects recurrence, survival...
5.
Xu D, Liang S, Su M, Yang H, Bruggmann R, Oberhaensli S, et al.
Lung Cancer
. 2024 Oct;
197:107986.
PMID: 39383772
Pleural mesothelioma (PM) is an aggressive cancer with limited treatment options. In particular, the frequent loss of tumor suppressors, a key oncogenic driver of the disease that is therapeutically intractable,...
6.
Jia Y, Liu Y, Yang H, Yao F
MedComm (2020)
. 2024 Sep;
5(9):e734.
PMID: 39263605
Adenoid cystic carcinoma (ACC) is a malignant tumor primarily originating from the salivary glands, capable of affecting multiple organs. Although ACC typically exhibits slow growth, it is notorious for its...
7.
Zhou S, Shan F, Cao Y, Huang P, Yang H, Liu S
Anal Chem
. 2024 Aug;
PMID: 39150789
miR-155 is a class of cancer markers closely related to cancer metastasis and invasion. Combining in situ detection with gene silencing not only helps to analyze the information on the...
8.
Xu D, Gao Y, Yang H, Spils M, Marti T, Losmanova T, et al.
JTO Clin Res Rep
. 2024 May;
5(5):100672.
PMID: 38715965
Introduction: Malignant pleural mesothelioma (MPM) is a rare and universally lethal malignancy with limited treatment options. Immunotherapy with immune checkpoint inhibitors (ICIs) has recently been approved for unresectable MPM, but...
9.
Minimally invasive surgery role in central squamous lung cancer after neoadjuvant chemoimmunotherapy
Fu S, Niu Y, Yang H, Fang W
J Thorac Dis
. 2024 Feb;
16(1):285-295.
PMID: 38410551
Background: The present body of literature provides restricted evidence concerning the application of video-assisted thoracoscopic surgery (VATS) in individuals diagnosed with centrally located, locally advanced, and initially surgically challenging squamous...
10.
Yang Z, Wang S, Yang H, Jiang Y, Zhu L, Zheng B, et al.
J Thorac Cardiovasc Surg
. 2024 Feb;
168(4):1245-1258.e17.
PMID: 38342430
Background: Neoadjuvant immunotherapy has ushered in a new era of perioperative treatment for resectable non-small cell lung cancer (NSCLC). However, large-scale data for verifying the efficacy and optimizing the therapeutic...